Lake Street analyst Eric Martinuzzi lowered the firm’s price target on Cellebrite (CLBT) to $21 from $23 and keeps a Buy rating on the shares. The firm, which anticipates a back half skewing to revenue, lowered its full year AEBITDA estimate to reflect a more conservative profit forecast.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLBT:
- Cellebrite price target lowered to $18 from $24 at Needham
- Cellebrite (CLBT): Sustained ARR Outperformance, Inseyets Migration, and Drone Forensics Upside Support Buy Rating
- Cellebrite price target lowered to $23 from $25 at TD Cowen
- Buy Rating Backed by ARR Acceleration, Conservative Margins, and 20%+ Upside from 2026 Growth Drivers
- Cellebrite sees Q1 revenue $126M-$128M, consensus $125.2M